LPNA Group, Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 0
- 0 authorized now
- Natural health products
- 24
- 13 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 0
Natural health products
Active licences first, newest first.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- ARANESP - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisMay 5, 2017 · Biologic or vaccine · Product safety
- KEYTRUDA (pembrolizumab) - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisMarch 20, 2017 · Biologic or vaccine
- REVOLADE (eltrombopag) - Risk of Severe HepatotoxicityAugust 25, 2016 · Drugs · Product safety
- XELODA (capecitabine) - Risk of Severe Skin Reactions - For the PublicDecember 3, 2013 · Drugs · Product safety
- XELODA (capecitabine) - Risk of Severe Skin Reactions - For Health ProfessionalsDecember 3, 2013 · Drugs · Product safety